{"groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"FG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"FG001","title":"ABVD"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"601"},{"groupId":"FG001","numSubjects":"586"}],"type":"Ongoing"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"11"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"44"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"29"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"664"},{"groupId":"FG001","numSubjects":"670"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"662"},{"groupId":"FG001","numSubjects":"659"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"664"},{"groupId":"FG001","numSubjects":"670"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with histologically confirmed diagnosis of advanced classical hodgkin lymphoma (cHL) were enrolled to receive: brentuximab vedotin 1.2 mg/kg plus doxorubicin 25 mg/m\\^2, vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2 (A+AVD) or doxorubicin 25 mg/m\\^2, bleomycin 10 units/m\\^2, vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2 (ABVD).","recruitmentDetails":"Participants took part in the study at 218 investigative sites in Asia Pacific, Europe, Latin America, and North America from 09 November 2012 to the primary completion date of 20 April 2017."}